1. Search Result
Search Result
Results for "

pathological diseases

" in MedChemExpress (MCE) Product Catalog:

76

Inhibitors & Agonists

16

Screening Libraries

1

Fluorescent Dyes

2

Biochemical Assay Reagents

8

Peptides

1

MCE Kits

13

Inhibitory Antibodies

8

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125864
    Fibrinogen (Bovine)
    2 Publications Verification

    Interleukin Related NF-κB Inflammation/Immunology
    Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
    Fibrinogen (Bovine)
  • HY-101855

    Anle138b

    Amyloid-β Neurological Disease
    Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .
    Emrusolmin
  • HY-137875

    N-Benzoyl-Gly-His-Leu hydrate

    Angiotensin-converting Enzyme (ACE) Amino Acid Derivatives Cardiovascular Disease
    Hippuryl-His-Leu-OH (N-Benzoyl-Gly-His-Leu) hydrate is a specific substrate for angiotensin-converting enzyme ACE I and is a molecular tool used for ACE activity detection in in vitro experiments. Hippuryl-His-Leu-OH hydrate is hydrolyzed by ACE through competitive binding. Under ACE catalysis, Hippuryl-His-Leu-OH hydrate undergoes hydrolysis to produce hippuric acid (HA). The amount of HA produced can be used to quantitatively assess ACE activity or screen for ACE inhibitors. The His-Leu released from Hippuryl-His-Leu-OH hydrate can also react with o-phthalaldehyde or Fluorescamine (HY-D0715) for fluorescence detection. Hippuryl-His-Leu-OH hydrate can be applied to the in vitro screening of ACE inhibitors for hypertension and cardiovascular diseases, and is also used in the study of changes in ACE activity during physiological and pathological processes such as renal compensatory hypertrophy .
    Hippuryl-His-Leu-OH hydrate
  • HY-111914A
    Ferroheme
    1 Publications Verification

    NO Synthase Fatty Acid Synthase (FASN) Cardiovascular Disease
    Ferroheme is the ferrous form of heme in hemoglobin, reversibly binding oxygen as an oxygen carrier. Its free form induces oxidative stress and ferroptosis by releasing iron ions, which catalyze reactive oxygen species generation via Fenton reactions, leading to lipid peroxidation and cell death. This mechanism is critical in pathological contexts like intracerebral hemorrhage and neurodegenerative diseases, making it a target for studying iron-overload disorders and ferroptosis-related pathologies[1][2][3].
    Ferroheme
  • HY-P991488

    Interleukin Related Inflammation/Immunology
    BI-765423 is a selective monoclonal antibody inhibitor targeting IL-11. BI-765423 blocks IL-11-mediated signaling, inhibits fibroblast activation, and can extend the healthy lifespan of mammals, counteract cellular senescence in human cells, and alleviate inflammatory aging-related pathological processes. BI-765423 is primarily used in research on fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) .
    BI-765423
  • HY-147423
    Zandatrigine
    1 Publications Verification

    NBI-921352; XEN901

    Sodium Channel Neurological Disease
    Zandatrigine (NBI-921352; XEN901) is a selective, orally active, voltage-gated sodium channel NaV1.6/SCN8A inhibitor that can penetrate the blood-brain barrier. Zandatrigine inhibits sodium influx by non-covalently binding to the VSD4 structure of NaV1.6, blocking the persistent and resuscitative currents under pathological conditions. Zandatrigine can reduce neuronal hyperexcitability and reduce epileptic seizures. Zandatrigine is 134-756-fold selective for other isoforms such as NaV1.1 and NaV1.2, and has minimal effect on NaV1.1 expressed by inhibitory interneurons. Zandatrigine can be used to study NaV1.6-mediated neuroexcitability diseases such as SCN8A-related developmental epileptic encephalopathy (SCN8A-DEE) and adult focal epilepsy .
    Zandatrigine
  • HY-NP004

    CVF

    Complement System Inflammation/Immunology
    Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) .
    Cobra Venom Factor
  • HY-P99471

    UCB 0107

    Tau Protein Neurological Disease
    Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease .
    Bepranemab
  • HY-B0531

    COX Phosphodiesterase (PDE) NF-κB NO Synthase Prostaglandin Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
    Triflusal
  • HY-19621

    HIF/HIF Prolyl-Hydroxylase Cancer
    THS-044 is a modulator of the formation of the HIF2α/ARNT heterodimer. THS-044 binding stabilizes the HIF2α PAS-B folded state (KD = 2 μM), for regulating HIF2 activity in endogenous and pathological settings, and does not bind to HIF1α or ARNT PAS-B. THS-044 can be used for the study of diseases related to hypoxia .
    THS-044
  • HY-113201

    Endogenous Metabolite Neurological Disease
    Tetradecanoylcarnitine is an acylcarnitine involved in mitochondrial β-oxidation of long-chain saturated fatty acids and fatty acid metabolism. Tetradecanoylcarnitine serves as a biomarker for very long-chain acyl-CoA dehydrogenase deficiency and MPTP (HY-15608)-induced Parkinson's disease. Tetradecanoylcarnitine exhibits a characteristic significant elevation in plasma levels in patients with sarcopenia, including those complicated with hypertension, and this elevation is closely associated with an increased risk of death. Tetradecanoylcarnitine is widely used in research on the pathological mechanisms of diseases such as Parkinson's disease and sarcopenia .
    Tetradecanoylcarnitine
  • HY-113355

    Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Endocrinology
    NADH is an orally active dehydrogenase coenzyme that acts as a crucial electron carrier in cellular respiration and participates in ATP production. NADH promotes metabolism, supports brain function, and counteracts oxidative stress by transferring electrons to the electron transport chain. As a signaling molecule, NADH regulates multiple biological processes, including anti-apoptosis, synaptic plasticity, gene expression, and calcium homeostasis. Redox imbalance of NADH/NAD⁺ is one of the key pathological mechanisms of various diseases, such as diabetic nephropathy, neurodegenerative diseases, and ischemia-reperfusion injury.
    NADH
  • HY-P10368

    Dynamin Reactive Oxygen Species (ROS) Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases .
    P110 heptapeptide
  • HY-D1244

    Fluorescent Dye Cardiovascular Disease Inflammation/Immunology
    CO probe 1 (probe 2) is a highly efficient fluorescent CO probe (Ex=493 nm) with an allyl ether reaction site. In the presence of PdCl₂, CO reduces Pd 2+ to Pd 0, triggering a Tsuji-Trost reaction that removes the allyl protecting group, releases fluorescein, and generates a significant fluorescence signal. CO probe 1 has high selectivity, rapid response (fluorescence enhancement of 150 times within 20 minutes), and low cytotoxicity, and can be used for real-time imaging of CO in living cells. CO probe 1 may be used to study pathological mechanisms involving CO signaling regulation, such as inflammation, vascular disease, or cancer .
    CO probe 1
  • HY-P990995

    E2814

    Tau Protein Neurological Disease
    Etalanetug (E2814) is a humanized high-affinity IgG1 antibody that targets tau protein and can cross the blood-brain barrier. Etalanetug inhibits the spread of pathological tau protein through high-affinity binding to the microtubule-binding region (MTBR). Etalanetug can be used in research related to Alzheimer's disease .
    Etalanetug
  • HY-44809

    HIF/HIF Prolyl-Hydroxylase Bacterial Cardiovascular Disease Infection Inflammation/Immunology
    Izilendustat is a potent prolyl hydroxylase inhibitor. Izilendustat competitively inhibits HIFPH2 activity, blocks HIF-1α degradation, stabilizes HIF-1α and HIF-2α proteins, and upregulates downstream target gene expression. Izilendustat can reduce intestinal inflammation and damage, enhance the ability of phagocytes to clear pathogens, and improve ischemia-related pathological phenotypes. Izilendustat can be used for the research of inflammatory bowel disease, ischemic vascular disease and anemia .
    Izilendustat
  • HY-N1570

    Salt-inducible Kinase (SIK) KLF Amyloid-β Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .
    Pterosin B
  • HY-19393

    Phosphodiesterase (PDE) Cardiovascular Disease Inflammation/Immunology Cancer
    SCH 351591 is a highly selective, orally active PDE4 inhibitor, with IC50 values of 58 nM and 153 nM in humans and rats, respectively. SCH 351591 effectively inhibits pathological processes such as cytokine production, eosinophilia, airway hyperresponsiveness and bronchospasm. SCH 351591 also induces microvascular injury, activates mast cells and endothelial cells, and causes increases in serum histamine and various inflammatory factors, leading to early vascular damage. SCH 351591 has been widely used in studies related to asthma, chronic obstructive pulmonary disease and drug-induced vascular injury .
    SCH 351591
  • HY-122974

    TSH Receptor Endocrinology
    VA-K-14 hydrochloride is a specific thyroid-stimulating hormone receptor (TSHR) antagonist (IC50= 12.3 μM) .
    VA-K-14 hydrochloride
  • HY-P99648

    BMS-986168; IPN007; BIIB092

    Tau Protein Neurological Disease
    Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
    Gosuranemab
  • HY-162566

    Calcium Channel Amyloid-β Neurological Disease
    REM127 is a small molecule compound capable of modulating calcium homeostasis in cells and possesses neuroprotective effects. REM127 can restore the calcium homeostasis imbalance in cellular models caused by pathological accumulation of tau protein. REM127 can efficiently cross the blood-brain barrier, and it has the potential to rescue synaptic and cognitive deficits in Alzheimer's disease animal models, as well as to slow down the progression of amyloid-beta and tau protein pathologies. REM127 can be used for research in neurodegenerative diseases .
    REM127
  • HY-125864C

    Biochemical Assay Reagents Cardiovascular Disease
    Porcine Fibrinogen is a coagulation protein, purified from porcine plasma with no plasminogen contained. Porcine Fibrinogen has excellent biocompatibility and does not induce aggregation of porcine platelets when in contact with porcine hepatocytes, aortic endothelial cells or hepatic sinusoidal endothelial cells. Porcine Fibrinogen is widely used in studies on the pathological mechanisms of cardiovascular diseases such as atherosclerosis and the development of related drugs .
    Porcine Fibrinogen
  • HY-P9995

    JNJ-63733657

    Tau Protein Neurological Disease
    Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
    Posdinemab
  • HY-118594

    Ferrochelatase Metabolic Disease
    Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate is an orally active porphyrin inducer and ferrochelatase inhibitor. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can induce small bile duct obstruction in mice, resulting in blocked bile excretion and causing cholestasis. Long-term use of Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can cause damage to bile duct epithelial cells, inflammatory responses, and liver fibrosis. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can be used to simulate the pathological features of cholestatic liver diseases such as sclerosing cholangitis (PSC) .
    Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate
  • HY-116753

    Amyloid-β Tau Protein Neurological Disease
    (-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .
    (-)Clausenamide
  • HY-E70226

    CTSS

    Ser/Thr Protease Cardiovascular Disease Inflammation/Immunology Cancer
    Cathepsin S, human, is a potent cysteine protease that promotes the degradation of damaged or harmful proteins in the endolysosomal pathway. Cathepsin S, human, is involved in multiple pathological processes, including arthritis, cancer, and cardiovascular disease .
    Cathepsin S, human
  • HY-P6374

    Dynamin Neurological Disease
    IIQLPEIVVV TFA is a specific inhibitor of Drp1-Mff interaction. IIQLPEIVVV TFA can distinguish physiological from pathological fission and block physiological fission, thus leading to mitochondrial dysfunction. IIQLPEIVVV TFA can be used in the study of Huntington's disease .
    IIQLPEIVVV TFA
  • HY-125287

    (Rac)-UCB0599; NPT200-11

    α-synuclein Neurological Disease
    (Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac)-Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac)-Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac)-Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) .
    (Rac)-Minzasolmin
  • HY-P99164

    LY3303560

    Tau Protein Neurological Disease
    Zagotenemab (LY3303560) is a humanized anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research .
    Zagotenemab
  • HY-149010

    Keap1-Nrf2 Neurological Disease
    NXPZ-2 is an orally active Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with a Ki value of 95 nM, EC50 value of 120 and 170 nM. NXPZ-2 can dose-dependently ameliorate Aβ[1-42]-Induced cognitive dysfunction, improve brain tissue pathological changes in Alzheimer’s disease (AD) mouse by increasing neuron quantity and function. NXPZ-2 can inhibit oxidative stress by increasing Nrf2 expression levels and promoting its cytoplasm to nuclear translocation, which is helpful for Keap1-Nrf2 PPI inhibitors and AD associated disease research .
    NXPZ-2
  • HY-103435
    Vialinin A
    2 Publications Verification

    Terrestrin A

    Deubiquitinase TNF Receptor E1/E2/E3 Enzyme Keap1-Nrf2 Inflammation/Immunology Cancer
    Vialinin A (Terrestrin A) is a p-terphenyl compound that can be derived from a Chinese edible mushroom. Vialinin A is an inhibitor of ubiquitin-specific peptidase 4 (USP4) and has anti-inflammatory and antioxidant properties. Vialinin A can alleviate cerebral ischaemia-reperfusion injury-induced neurological deficits and neuronal apoptosis. Vialinin A promotes activation of Keap1-Nrf2-ARE signaling pathway and increases the protein degradation of Keap1. Vialinin A possesses various pharmacological activities in cancer, Kawasaki disease, asthma, and pathological scarring. Vialinin A is a potent inhibitor of TNF-α, USP4, USP5, and sentrin/SUMO-specific protease 1 (SENP1). Vialinin A can be studied in reseach for autoimmune diseases, cancer and ischaemic stroke .
    Vialinin A
  • HY-P99830

    KH902

    VEGFR TNF Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology Cancer
    Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC50 = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (Kd = 0.5 pM), VEGF-B (Kd = 8 pM), VEGF-C, and PlGF (Kd = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .
    Conbercept
  • HY-116586

    Sigma Receptor mAChR ERK Amyloid-β Tau Protein Neurological Disease
    AF710B is an orally effective allosteric agonist for the M1 muscarinic receptor and σ1 receptor. AF710B activates the downstream phosphorylated ERK1/2 and phosphorylated CREB signaling pathways. AF710B simultaneously improves cognitive function and alleviates the core pathological features of Alzheimer's disease, including deposition, excessive Tau phosphorylation and neuroinflammation. AF710B is applicable to the research of Alzheimer's disease .
    AF710B
  • HY-P11005

    Dynamin ATP Synthase Neurological Disease
    P259 is a Drp1-Mff inhibitor. P259 distinguishes physiological from pathological fission by specifically inhibiting Drp1-Mff interaction. P259 elongates cell mitochondria and disrupts mitochondrial function and motility. P259 reduces ATP levels and alters mitochondrial structure in the brain, resulting in behavioral deficits in wild-type mice and a short lifespan in Huntington's disease (HD) mice model .
    P259
  • HY-116392E

    Glucosylceramide Synthase (GCS) Apoptosis Neurological Disease Metabolic Disease Cancer
    D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP can be used to study diseases related to targeted glycosphingolipid metabolism .
    D-threo-PDMP
  • HY-116392F

    Glucosylceramide Synthase (GCS) Neurological Disease Metabolic Disease Cancer
    D-threo-PDMP hydrochloride is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP hydrochloride inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP hydrochloride inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP hydrochloride can be used to study diseases related to targeted glycosphingolipid metabolism .
    D-threo-PDMP hydrochloride
  • HY-151240

    Endogenous Metabolite Neurological Disease
    Galactosylceramide (GalC) is a galactosylceramide that has been implicated in many physiological and pathological phenomena. For example, important lysosomal storage disorders such as Gaucher disease (GD) and neurodegenerative diseases are characterized by GlcCer accumulation.
    Galactosylceramide
  • HY-125864D

    Interleukin Related NF-κB Cardiovascular Disease
    Rabbit Fibrinogen is a native fibrinogen from rabbit plasma. Fibrinogen is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
    Rabbit Fibrinogen
  • HY-W414548

    Others Neurological Disease Metabolic Disease
    7α,27-Dihydroxycholesterol is an oxysterol characterized by its oxidized side chains and is produced through the hydroxylation of 27-Hydroxycholesterol (27-OHC); it serves as a metabolite of interest in lipidomic analyses of various pathological conditions, including neurological diseases, Smith-Lemli-Opitz syndrome, obesity metabolic syndrome, and diabetes. Notably, levels of 7α,27-di-OHC decrease following lipopolysaccharide activation, and it also functions as a ligand for Epstein-Barr virus-induced gene 2 (EBI2). Additionally, 7α,27-di-OHC exists as a structural isomer of 7α,25-dihydroxycholesterol (7α25-OHC).
    7α,27-Dihydroxycholesterol
  • HY-P991168

    Amyloid-β CCR Neurological Disease Inflammation/Immunology
    Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .
    Velaprumig
  • HY-W835959

    Tau Protein Neurological Disease
    ACI-3024 is an an orally active and highly selective Tau protein aggregation inhibitor. ACI-3024 decrease the β-sheet content and seeding properties of pathological Tau from different Tauopathies, leading to a significant rescue of the Tau-induced neurodegeneration and neuroinflammation in a cellular model. ACI-3024 is promising for research of neurodegenerative diseases .
    ACI-3024
  • HY-P2516

    Tau Protein Neurological Disease
    Tau Peptide (275-305) (Repeat 2 domain) is the Alzheimer's Tau fragment R2, corresponding to the second repeat unit of the microtubule-binding domain, which is believed to be pivotal to the biochemical properties of full tau protein. Tau Peptide (275-305) specifically coordinates with group IIB metal ions (Zn²⁺, Cd²⁺, Hg²⁺), which can induce their conformational changes and significantly promote their pathological accumulation. Tau Peptide (275-305) can be used to study the role of heavy metals in neurodegenerative diseases .
    Tau Peptide (275-305) (Repeat 2 domain)
  • HY-134268

    8-Bromo-7-deazaadenosine-5'-O-diphosphoribose

    TRP Channel Cardiovascular Disease Neurological Disease Metabolic Disease
    8-Br-7-CH-ADPR (8-Bromo-7-deazaadenosine-5'-O-diphosphoribose) is a specific TRPM2 antagonist that inhibits TRPM2 activation by binding to the NUDT9 homology domain of the TRPM2 channel, thereby controlling the influx of cations through the cell membrane channel. 8-Br-7-CH-ADPR can be used to study the role of TRPM2 in pathological processes such as cell death, neurodegenerative diseases, myocardial infarction, and diabetes .
    8-Br-7-CH-ADPR
  • HY-P4551

    N-Benzoyl-Gly-His-Leu

    Angiotensin-converting Enzyme (ACE) Amino Acid Derivatives Cardiovascular Disease
    Hippuryl-His-Leu-OH (N-Benzoyl-Gly-His-Leu) is a specific substrate for angiotensin-converting enzyme (ACE I) and a molecular tool used for ACE activity detection in in vitro experiments. Hippuryl-His-Leu-OH is hydrolyzed by ACE through competitive binding. Under ACE catalysis, Hippuryl-His-Leu-OH undergoes hydrolysis to produce hippuric acid (HA). The amount of HA produced can be used to quantitatively assess ACE activity or screen for ACE inhibitors. The released His-Leu can also react with o-phthalaldehyde or Fluorescamine (HY-D0715) for fluorescence detection. Hippuryl-His-Leu-OH can be applied to the in vitro screening of ACE inhibitors for hypertension and cardiovascular diseases, and is also used in the study of ACE activity changes in physiological and pathological processes such as renal compensatory hypertrophy .
    Hippuryl-His-Leu-OH
  • HY-108120

    Angiotensin Receptor Cardiovascular Disease
    L-162537 is a competitive human angiotensin II receptor 1 (AT1) and receptor 2 (AT2) antagonist with an IC50=1.7 nM for AT1. L-162537 inhibits Ang II-mediated vasoconstriction, blood pressure elevation and related pathological signaling pathways. L-162537 is promising for research of angiotensin II-related cardiovascular diseases such as hypertension .
    L-162537
  • HY-P10319

    PKA Cardiovascular Disease Cancer
    RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .
    RI-STAD-2
  • HY-N1570R

    Reference Standards Salt-inducible Kinase (SIK) KLF Amyloid-β Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Pterosin B (Standard) is the analytical standard of Pterosin B (HY-N1570). This product is intended for research and analytical applications. Pterosin B is an indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .
    Pterosin B (Standard)
  • HY-148514

    PDGFR Cancer
    CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer .
    CT52923
  • HY-E70228

    Ser/Thr Protease Cancer
    Cathepsin H, human liver is an aminopeptidase and an endopeptidase. Involved in the catabolism of proteins in the lysosomal system. Cathepsin H, human liver has a key role in the regulation of the biological behavior of tumor cells and the pathological processes of brain diseases .
    Cathepsin H, human liver
  • HY-163885
    SSZ
    1 Publications Verification

    Cholinesterase (ChE) Beta-secretase γ-secretase Neurological Disease
    SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice .
    SSZ

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: